CytomX Therapeutics, Inc. (CTMX) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

9/25

Growth 2 Margin 1 Expansion 4 Platform 0 Financial 2

latest quarter score

Earnings Reports

9
CytomX (CTMX) Q3 2025: CX2051 Patient Enrollment Surges to 100, Pivots Toward Registrational Path
August 07, 2026
9
CytomX Therapeutics (CTMX) Q1 2026: Cash Runway Extends to 2028 as Varsetta-M Enrollment Hits 113
May 08, 2026
10
CytomX (CTMX) Q4 2025: Varsetta-M Delivers 32% ORR at 10mg, Accelerating CRC ADC Path
March 16, 2026
9
CytomX (CTMX) Q3 2025: CX2051 Study Enrollment Surges to 100, Pivots Toward Registrational Path
November 07, 2025
9
CyTOMICS (CTMX) Q2 2025: $100M Raise Extends Runway, CX2051 Data Sets Stage for CRC Push
August 08, 2025
11
CytomX Therapeutics (CTMX) Q1 2025: CX-2051 Demonstrates 28% Response Rate, Paving Path to Phase 2 Launch
May 12, 2025
CytomX Therapeutics (CTMX) Q4 2024: CX-2051 Dose Escalation Advances Toward Therapeutic Range in Colorectal Cancer
March 06, 2025

Browse all companies